» Articles » PMID: 39400335

Comparative Diagnostic Efficacy of Abbreviated and Full Protocol Breast MRI: a Systematic Review and a Meta-analysis

Abstract

Objectives: This meta-analysis compares the efficacy, limitations, and clinical implications of abbreviated breast MRI (AB-MRI) and full protocol MRI (FP-MRI), focusing on diagnostic accuracy across diverse populations. It extends previous analyses by including studies conducted after 2019 in both screening and diagnostic contexts.

Methods: We conducted a systematic review (November 2019 to December 2022), using a bivariate model to calculate summary estimates of sensitivity and specificity. Random effect models were applied for summary area under the curve (AUC), and probability distributions for negative and positive predictive values were obtained. Subgroup analyses explored differences in sensitivity, specificity, and AUC between AB-MRI and FP-MRI.

Results: From 11 eligible studies (1 prospective, 10 retrospective), statistical analysis revealed a significant difference in sensitivity between FP-MRI (95%) and AB-MRI (86%, P = .005), with no significant difference in specificity (P = .50). AB-MRI's shorter acquisition time suggests potential for higher patient throughput, but challenges remain in detecting small lesions and nonmass enhancements. Some studies recommend additional sequences, like diffusion-weighted imaging, to improve diagnostic performance.

Conclusions: While FP-MRI remains the gold standard in breast cancer detection, AB-MRI offers a quicker alternative, especially in high-risk screening. However, its lower sensitivity limits its use as a standalone diagnostic tool. Future research should optimize AB-MRI protocols and consider patient-specific factors to enhance breast cancer screening and diagnostic strategies.

Advances In Knowledge: This meta-analysis expands understanding of AB-MRI's role in breast cancer detection, highlighting its benefits and limitations compared to FP-MRI, particularly in terms of sensitivity and screening efficiency.

References
1.
Marquina Martinez D, Cruz Ciria S, Garcia Barrado A, Sunen Amador I, Garcia Mur C . Value of an abbreviated protocol of breast magnetic resonance imaging for screening high-risk patients. Radiologia (Engl Ed). 2019; 62(3):198-204. DOI: 10.1016/j.rx.2019.08.001. View

2.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

3.
Pesapane F, Battaglia O, Pellegrino G, Mangione E, Petitto S, Manna E . Advances in breast cancer risk modeling: integrating clinics, imaging, pathology and artificial intelligence for personalized risk assessment. Future Oncol. 2023; 19(38):2547-2564. DOI: 10.2217/fon-2023-0365. View

4.
Drinkovic M, Drinkovic I, Milevcic D, Matijevic F, Drinkovic V, Markotic A . Diagnostic and Practical Value of Abbreviated Contrast Enhanced Magnetic Resonance Imaging in Breast Cancer Diagnostics. Cancers (Basel). 2022; 14(22). PMC: 9688876. DOI: 10.3390/cancers14225645. View

5.
Kizildag Yirgin I, Engin G, Yildiz S, Aydin E, Karanlik H, Cabioglu N . Abbreviated and Standard Breast MRI in Neoadjuvant Chemotherapy Response Evaluation: A Comparative Study. Curr Med Imaging. 2022; 18(10):1052-1060. DOI: 10.2174/1573405618666220223142009. View